Literature DB >> 1723488

Avian myeloblastosis virus reverse transcriptase inhibition by nalidixic acid.

H Aoyama1.   

Abstract

Nalidixic acid, a very specific inhibitor of bacterial DNA synthesis, has been studied for its action on the avian myeloblastosis virus reverse transcriptase activity. The drug inhibited the DNA synthesis reaction catalyzed by the viral enzyme in the presence of different template-primers. The inhibitory effect by nalidixic acid was higher with polyriboadenylic acid than with polyribocytidylic acid as a synthetic template. With activated DNA as a template nalidixic acid preferentially inhibited the TMP incorporation when compared with the dAMP incorporation. Both these results showed the importance of the presence of adenine in the templates for a more efficient inhibition by nalidixic acid. The inhibition for this drug was also shown in the presence of Mn2+ instead of Mg2+ as the divalent cation, and with a 2'-fluorinated analogue of polyriboadenylic acid as the template. Kinetic data showed a non-competitive inhibition by nalidixic acid in relation to polyriboadenylic acid and to TTP in the reaction catalyzed by reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723488     DOI: 10.1007/bf00233122

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  27 in total

1.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

2.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

Authors:  L L Shen; W E Kohlbrenner; D Weigl; J Baranowski
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

3.  Comparative ability of RNA and DNA to prime DNA synthesis in vitro: role of sequence, sugar, and structure of template-primer.

Authors:  T M Tamblyn; R D Wells
Journal:  Biochemistry       Date:  1975-04-08       Impact factor: 3.162

4.  The induction of protein X in DNA repair and cell division mutants of Escherichia coli.

Authors:  L J Gudas
Journal:  J Mol Biol       Date:  1976-07-05       Impact factor: 5.469

5.  Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.

Authors:  P Hussy; G Maass; B Tümmler; F Grosse; U Schomburg
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

6.  Bactericidal action of nalidixic acid on Bacillus subtilis.

Authors:  T M Cook; K G Brown; J V Boyle; W A Goss
Journal:  J Bacteriol       Date:  1966-11       Impact factor: 3.490

7.  Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.

Authors:  G Seibert; M Limbert; N Klesel
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

8.  Nalidixic acid, oxolinic acid, and novobiocin inhibit yeast glycyl- and leucyl-transfer RNA synthetases.

Authors:  H T Wright; K C Nurse; D J Goldstein
Journal:  Science       Date:  1981-07-24       Impact factor: 47.728

9.  MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS.

Authors:  W A GOSS; W H DEITZ; T M COOK
Journal:  J Bacteriol       Date:  1965-04       Impact factor: 3.490

10.  Dependence of mammalian DNA synthesis on DNA supercoiling. III. Characterization of the inhibition of replicative and repair-type DNA synthesis by novobiocin and nalidixic acid.

Authors:  M R Mattern; D A Scudiero
Journal:  Biochim Biophys Acta       Date:  1981-04-27
View more
  1 in total

1.  Inhibition of the wheat germ DNA polymerase A activity by the antiviral drug HPA-23.

Authors:  H Aoyama; M B Jucá; M Castroviejo; S Litvak
Journal:  Plant Mol Biol       Date:  1993-12       Impact factor: 4.076

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.